U.S. FDA approves Mylan generic of Lilly lung cancer drug Alimta


Aug 29 (Reuters) - The U.S. Food and Drug Administration on Thursday granted Mylan NV MYL.O tentative approval for its generic version of Eli Lilly and Co's LLY.N lung cancer drug Alimta.

Shares of Mylan closed up 3.9% at $19.90 on Thursday.

A tentative approval generally signals that the FDA has signed off on the company's marketing application, but that it cannot sell the medicine until the U.S. patents have expired.

Lilly stands to lose U.S. patent protection on the chemotherapy drug, known generically as pemetrexed, in 2022.

Earlier this month, Lilly won a federal appeals court decision protecting its patent from copycat drugs by Pfizer Inc PFE.N and India's Dr Reddy's Laboratories Ltd.

Alimta is Lilly's third biggest-selling drug. The Indianapolis-based drugmaker reported second-quarter sales of $577.8 million for the medicine.

(Reporting by Tamara Mathias in Bengaluru; editing by Bill Berkrot)

((Tamara.Mathias@thomsonreuters.com; within U.S. +1 646 223 8780, outside U.S. +91 806749 1208;))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Info icon

This data feed is not available at this time.

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.